US Market News
1月前
Emerson Unveils AI-Ready Test Automation Platform at Annual NI Connect ConferenceMay 13, 2026 11:00 AM
PR Newswire (US) NI Nigel™ AI to expand into code generation and cross-platform intelligence, embedding AI automation across the test lifecycle FORT WORTH, Texas, May 13, 2026 /PRNewswire/ -- Global automation leader Emerson (NYSE: EMR) today announced the expansion of NI Nigel™ AI across its test software portfolio, introducing new prompt-based code generation in the NI LabVIEW+ Suite and further evolving the NI platform into an integrated, AI-ready test automation platform. These enhancements will allow aerospace, semiconductor, transportation and other mission-critical customers to develop, test and deliver products to market faster while meeting strict reliability and safety requirements. Nigel AI is a test-optimized AI technology designed to operate within the rigor and constraints of test engineering environments. The enhancements, expected to be available later in 2026, will enable engineers to further accelerate test development while maintaining transparency and control. Nigel AI will also expand across its full software portfolio, including NI FlexLogger™, NI InstrumentStudio™, NI TestStand™ and NI SystemLink™, providing context-aware guidance across the test lifecycle – from development and reuse to validation and deployment."The NI platform has evolved through every major shift in technology, continually improving how test engineers reach their goals," said Ritu Favre, president of Emerson's test and measurement business. "As AI reshapes product development, it's this adaptability that allows our AI-ready platform to stand out. The real strength of the NI platform isn't any single capability; it's in the integration of hardware, software, data and ecosystem that engineers can rely on as technology continues to evolve."Built to support the growing complexity and automation demands of modern technology, the NI platform unifies modular hardware, open software and a data foundation designed for scale. By embedding AI into everyday engineering tools, Emerson enables engineering teams to move faster and make better decisions without compromising measurement integrity or system reliability. For example, in internal testing, Emerson engineers have used Nigel to reduce test development and troubleshooting from days or hours to minutes.At the hardware level, the NI platform delivers low size, weight and power consumption while ensuring high configurability and supporting diverse signals, precise timing and high-performance data movement for demanding test applications.NI software connects operating environments and computing technologies, allowing test workflows to evolve and incorporate AI naturally over time.A shared data foundation simplifies the capture, management and reuse of measurement data, enabling analytics, collaboration and long-term system optimization across teams and sites.During NI Connect keynote presentations, companies including NVIDIA, Alstom, Valeo, Zap Energy and Cyth Systems shared how they are using Emerson's NI test and measurement technologies to accelerate development and validation of next-generation products.Follow the latest NI Connect event announcements via our social channels: LinkedIn, Instagram, Facebook, X and YouTube.About Emerson
Emerson (NYSE: EMR) is a global automation leader delivering solutions for the most demanding technology challenges. Headquartered in St. Louis, Missouri, Emerson is engineering the autonomous future, enabling customers to optimize operations and accelerate innovation. For more information, visit Emerson.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/emerson-unveils-ai-ready-test-automation-platform-at-annual-ni-connect-conference-302766280.htmlSOURCE Emerson Original: Emerson Unveils AI-Ready Test Automation Platform at Annual NI Connect Conference
US Market News
1月前
L&T Technology Services und Emerson geben eine weltweite Zusammenarbeit und strategische Partnerschaft bekannt, um Innovationen im Bereich Engineering Excellence voranzutreibenMay 12, 2026 3:39 PM
Business Wire Ihre Partnerschaft im im Bereich Nachhaltigkeit bringt die technischen Fähigkeiten von LTTS mit der Testplattform NI von Emerson zusammen, um die System-Integration und die Produktentwicklung branchenübergreifend zu beschleunigen und zu entwickeln L&T Technology Services (BSE: 540115, NSE: LTTS), ein weltweit führender Anbieter von Forschungs- und Entwicklungsdienstleistungen in den Bereichen KI, Digitalisierung und Ingenieurwesen, gab heute eine strategische globale Partnerschaft mit Emerson (NYSE: EMR) bekannt, einem weltweit führenden Unternehmen im Bereich Automatisierung und Anbieter fortschrittlicher Test- und Messlösungen. Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260511243583/de/L&T Technology Services and Emerson announce strategic global partnership. Seen in the picture: Senior leaders and delegates from L&T Technology Services and Emerson’s Test & Measurement business, including the NI leadership team. Im Rahmen dieses Engagements wird LTTS als globaler Systemintegrator und Partner für die Technologieentwicklung fungieren und die Konzeption, Implementierung sowie die Lebenszyklusunterstützung fortschrittlicher Systemengineering-Plattformen branchenübergreifend begleiten. Im Rahmen der Partnerschaft werden zudem gemeinsame Ansätze für Kundenprojekte eingeführt, wodurch sich LTTS als wichtiger Systemintegrationspartner für die NI-Testplattform positioniert. Im Mittelpunkt der Zusammenarbeit stehen die Produktentwicklung und die Entwicklung maßgeschneiderter Lösungen für verschiedene Branchen, darunter Industrie, Transportwesen, Halbleiterindustrie sowie Luft- und Raumfahrt und Verteidigung, in denen Systemleistung, Ausfallsicherheit und Nachhaltigkeit von entscheidender Bedeutung sind. Im Rahmen der Partnerschaft wird LTTS an seinem Campus in Mysuru in Indien ein eigenes Kompetenzzentrum (Centre of Excellence, CoE) einrichten. Das Kompetenzzentrum wird auf der Test- und Messplattform von NI basieren und als globale Drehscheibe für die gemeinsame Lösungsentwicklung, Industrialisierung und angewandte Innovation dienen, wobei NI-Software und -Hardware genutzt werden, um die Produktentwicklung und das Engineering sowie die Arbeitsabläufe in den Bereichen Testautomatisierung und Validierung zu beschleunigen. Zu den wichtigsten Schwerpunkten zählen zudem gemeinsame Markteinführungsinitiativen, die Entwicklung branchenspezifischer Lösungen, die Lizenzbereitstellung sowie erweiterte Kundensupportmodelle. Ritu Favre, Präsidentin des Geschäftsbereichs Test and Measurement bei Emerson, sagte: „Technische Umgebungen werden zunehmend softwaregesteuert, datenzentriert und vernetzt. Unsere offene, modulare NI-Plattform bietet die architektonische Grundlage, die Unternehmen benötigen, um die zunehmende Systemkomplexität zu bewältigen und gleichzeitig Validierungs- und Bereitstellungszyklen zu beschleunigen. Durch unsere Zusammenarbeit mit LTTS als globalem Systemintegrator erweitern wir diese Plattform um branchenspezifische Implementierungen, die unseren Kunden helfen, den Übergang von der Unsicherheit in der Entwicklung zur Sicherheit im Betrieb zu meistern. Dabei nutzen wir die bewährte Technologieführerschaft der automatisierten Test- und Messlösungen von NI. Alind Saxena, Geschäftsführer und Leiter des Bereichs Strategische Initiativen und Wachstumsmärkte, sagte: „Unsere Kunden aus den Bereichen Mobilität, Nachhaltigkeit und Technologie benötigen technische Systeme, die intelligent, anpassungsfähig und zukunftsfähig sind. Unsere Partnerschaft mit Emerson stärkt die Fähigkeit von LTTS, solche Systeme in großem Maßstab zu konzipieren und zu realisieren. Durch die Kombination der technologischen Führungsrolle von NI mit der fundierten technischen Expertise von LTTS schaffen wir eine solide Grundlage für die langfristige Wertschöpfung in industriellen Ökosystemen.“ Über L&T Technology Services Ltd L&T Technology Services (LTTS) ist ein weltweit führender Anbieter von Beratungsdienstleistungen in den Bereichen KI, Digital & ER&D. Als börsennotierte Tochtergesellschaft von Larsen & Toubro (L&T) bieten wir Design-, Entwicklungs-, Test- und Wartungsdienstleistungen für Produkte und Prozesse an. Zielgerichtet. Agil. Innovativ. So treiben wir das Wachstum in den Segmenten Mobilität, Nachhaltigkeit und Tech voran. Zu unseren Kunden zählen 69 Fortune-500-Unternehmen und 57 Top ER&D-Unternehmen. Sie kommen aus den Branchen Industrie, Medizingeräte, Transport, Telekom & Hi-Tech sowie Prozessindustrie. Der Hauptsitz des Unternehmens befindet sich in Indien. Am 31. März 2026 beschäftigten wir mehr als 23.800 Mitarbeiter in 22 globalen Designzentren, 31 globalen Vertriebsbüros und 98 Innovationslabs. Mehr Informationen über L&T Technology Services finden Sie unter: www.LTTS.com. Über Emerson Emerson (NYSE: EMR) ist ein weltweit führender Anbieter von Automatisierungslösungen für die anspruchsvollsten technischen Herausforderungen. Das Unternehmen Emerson mit Hauptsitz in St. Louis, Missouri, gestaltet die autonome Zukunft und ermöglicht es seinen Kunden, ihre Betriebsabläufe zu optimieren und Innovationen voranzutreiben. Für weitere Informationen besuchen Sie Emerson.com. Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab. Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260511243583/de/ Medienkontakt:
Aniruddha Basu
L&T Technology Services Limited
E-Mail: Aniruddha.Basu@LTTS.com Sayanti Chakraborty
L&T Technology Services Limited
E-Mail: Sayanti.Chakraborty@LTTS.com Original: L&T Technology Services und Emerson geben eine weltweite Zusammenarbeit und strategische Partnerschaft bekannt, um Innovationen im Bereich Engineering Excellence voranzutreiben
US Market News
1月前
L&T Technology Services et Emerson annoncent un partenariat mondial et un engagement stratégique visant à stimuler l'innovation dans le domaine de l'excellence techniqueMay 12, 2026 3:39 PM
Business Wire Ce partenariat dans le domaine du développement durable associe les compétences techniques de LTTS à la plateforme de test NI d'Emerson afin d'accélérer l'intégration des systèmes et le développement de produits dans de nombreux secteurs d'activité L&T Technology Services (BSE : 540115, NSE : LTTS), leader mondial des services de R&D en intelligence artificielle, dans le numérique et en ingénierie, a annoncé aujourd’hui un partenariat stratégique mondial avec Emerson (NYSE : EMR), leader mondial de l’automatisation et fournisseur de solutions avancées de test et de mesure. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260511571314/fr/L&T Technology Services and Emerson announce strategic global partnership. Seen in the picture: Senior leaders and delegates from L&T Technology Services and Emerson’s Test & Measurement business, including the NI leadership team. Dans le cadre de cet accord, LTTS agira en tant qu'intégrateur de systèmes mondial et partenaire de développement technologique, en soutenant la conception, le déploiement et la gestion du cycle de vie de plateformes d'ingénierie système avancées dans tous les secteurs. Ce partenariat introduit également des approches collaboratives pour les projets clients, positionnant LTTS comme un partenaire clé en intégration de systèmes pour la plateforme de test NI. La collaboration se concentrera sur l'ingénierie produit et le développement de solutions sur mesure pour de nombreux secteurs, notamment l'industrie, les transports, les semi-conducteurs, l'aérospatiale et la défense, où les performances, la résilience et la durabilité des systèmes sont essentielles. Dans le cadre de ce partenariat, LTTS mettra en place un Centre d'excellence (CoE) dédié sur son campus de Mysuru, en Inde. Le CoE s'appuiera sur la plateforme de test et de mesure de NI et servira de pôle mondial pour le développement conjoint de solutions, l'industrialisation et l'innovation appliquée, en s'appuyant sur les logiciels et le matériel de NI pour accélérer le développement et l'ingénierie des produits, ainsi que les workflows d'automatisation des tests et de validation. Les principaux domaines d'action comprennent également des initiatives conjointes de mise sur le marché, le développement de solutions spécifiques à chaque secteur, l'activation de licences et des modèles de support client étendus. Ritu Favre, présidente de la division Test et Mesure d’Emerson, a déclaré : « Les environnements d'ingénierie sont de plus en plus définis par les logiciels, centrés sur les données et interconnectés. Notre plateforme NI ouverte et modulaire offre la base architecturale dont les entreprises ont besoin pour gérer la complexité croissante des systèmes tout en accélérant les cycles de validation et de déploiement. Grâce à notre collaboration avec LTTS, intégrateur de systèmes à l'échelle mondiale, nous étendons cette plateforme à des implémentations spécifiques à chaque secteur, qui aident nos clients à passer de l'incertitude technique à la confiance opérationnelle, tout en profitant du leadership technologique éprouvé des solutions de test et de mesure automatisées de NI. » Alind Saxena, directeur exécutif et président – Initiatives stratégiques et marchés en croissance, a déclaré : « Nos clients dans les domaines de la mobilité, du développement durable et des technologies ont besoin de systèmes d’ingénierie intelligents, adaptables et prêts pour l’avenir. Notre partenariat avec Emerson renforce la capacité de LTTS à concevoir et à déployer de tels systèmes à grande échelle. En combinant le leadership technologique de NI avec l’expertise technique approfondie de LTTS, nous créons une base solide pour la création de valeur à long terme dans l’ensemble des écosystèmes industriels. » À propos de L&T Technology Services Ltd L&T Technology Services (LTTS) est un leader mondial dans le domaine des services de conseil en IA, numérique et ER&D. Filiale cotée en bourse de Larsen & Toubro (L&T), nous offrons des services de conception, de développement, de test et de maintenance pour tous les produits et processus. Détermination. Agilité. Innovation. C’est ainsi que nous stimulons la croissance dans les segments de la mobilité, de la durabilité et de la technologie. Notre clientèle comprend 69 entreprises du classement Fortune 500 et 57 grandes entreprises d’ER&D dans les secteurs des produits industriels, des dispositifs médicaux, des transports, des télécommunications et des technologies de pointe, ainsi que des industries de transformation. Basés en Inde, nous comptons plus de 23 800 employés dans 22 centres de conception mondiaux, 31 bureaux de vente mondiaux et 98 laboratoires d’innovation au 31 mars 2026. Pour plus d’informations sur L&T Technology Services, rendez-vous sur www.LTTS.com. À propos d’Emerson Emerson (NYSE : EMR) est un leader mondial de l'automatisation qui propose des solutions répondant aux défis technologiques les plus exigeants. Basée à Saint-Louis, dans le Missouri, Emerson façonne l'avenir de l'autonomie, permettant ainsi à ses clients d'optimiser leurs opérations et d'accélérer l'innovation. Pour plus d'informations, rendez-vous sur Emerson.com. Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence. Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260511571314/fr/ Contact presse :
Aniruddha Basu
L&T Technology Services Limited
E : Aniruddha.Basu@LTTS.com Sayanti Chakraborty
L&T Technology Services Limited
E : Sayanti.Chakraborty@LTTS.com Original: L&T Technology Services et Emerson annoncent un partenariat mondial et un engagement stratégique visant à stimuler l'innovation dans le domaine de l'excellence technique
US Market News
1月前
L&T Technology Services and Emerson Announce a Global Cooperation and Strategic Engagement to Drive Innovation in Engineering ExcellenceMay 12, 2026 5:30 AM
Business Wire Partnership in its Sustainability segment brings together LTTS’ engineering capabilities and Emerson’s NI test platform to accelerate system integration and product development across multiple industries L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital and Engineering R&D services, today announced a strategic global partnership with Emerson (NYSE: EMR), a global automation leader and provider of advanced test and measurement solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511346343/en/L&T Technology Services and Emerson announce strategic global partnership. Seen in the picture: Senior leaders and delegates from L&T Technology Services and Emerson’s Test & Measurement business, including the NI leadership team. Under this engagement, LTTS will serve as a global System Integrator and technology development partner, supporting the design, deployment and lifecycle enablement of advanced systems engineering platforms across industries. The partnership also introduces joint engagement approaches for customer projects, positioning LTTS as a key system integration partner for the NI test platform. The collaboration will focus on product engineering and solution development tailored for multiple sectors including Industrial, Transportation, Semiconductors, Aerospace & Defense where system performance, resilience and sustainability are critical. As part of the partnership, LTTS will establish a dedicated Centre of Excellence (CoE) at its Mysuru campus in India. The CoE will be based on the NI test and measurement platform and will function as a global hub for joint solution development, industrialization and applied innovation, leveraging NI software and hardware to accelerate product development and engineering, test automation and validation workflows. Key focus areas also include joint go-to-market initiatives, development of industry-specific solutions, license enablement and extended client support models. Ritu Favre, President for Emerson’s Test and Measurement business, said, “Engineering environments are becoming increasingly software defined, data centric and interconnected. Our open, modular NI platform provides the architectural foundation organizations need to manage growing system complexity while accelerating validation and deployment cycles. Through our collaboration with LTTS as a global system integrator, we extend this platform into industry-specific implementations that help customers move from engineering uncertainty to operational confidence and leveraging the proven technology leadership of NI automated test and measurement solutions.” Alind Saxena, Executive Director & President – Strategic Initiatives & Growth Markets, said, “Our clients in Mobility, Sustainability and Tech require engineering systems that are intelligent, adaptable and future-ready. Our partnership with Emerson strengthens LTTS’ ability to architect and deploy such systems at scale. By combining NI’s technology leadership with LTTS’ engineering depth, we are creating a powerful foundation for long-term value creation across industrial ecosystems.” About L&T Technology Services Ltd L&T Technology Services (LTTS) is a global leader in AI, Digital & ER&D Consulting Services. A listed subsidiary of Larsen & Toubro (L&T), we offer design, development, testing, and sustenance services across products and processes. Purposeful. Agile. Innovation. is how we drive growth across the Mobility, Sustainability and Tech segments. Our customer base includes 69 Fortune 500 companies and 57 top ER&D companies across industrial products, medical devices, transportation, telecom & hi-tech, and process industries. Headquartered in India, we have over 23,800 employees across 22 global design centers, 31 global sales offices, and 98 innovation labs, as of March 31, 2026. For additional information about L&T Technology Services log on to www.LTTS.com. About Emerson Emerson (NYSE: EMR) is a global automation leader delivering solutions for the most demanding technology challenges. Headquartered in St. Louis, Missouri, Emerson is engineering the autonomous future, enabling customers to optimize operations and accelerate innovation. For more information, visit Emerson.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511346343/en/ Media Contact:
Aniruddha Basu
L&T Technology Services Limited
E: Aniruddha.Basu@LTTS.com Sayanti Chakraborty
L&T Technology Services Limited
E: Sayanti.Chakraborty@LTTS.com Original: L&T Technology Services and Emerson Announce a Global Cooperation and Strategic Engagement to Drive Innovation in Engineering Excellence
US Market News
2月前
Jennifer Newstead to Join Emerson's Board of DirectorsMay 5, 2026 4:06 PM
PR Newswire (US) ST. LOUIS, May 5, 2026 /PRNewswire/ -- Emerson (NYSE: EMR) today announced the election of Jennifer Newstead, Senior Vice President and General Counsel at Apple, to its Board of Directors, effective August 3, 2026. She will serve on the Compensation Committee and the Corporate Governance and Nominating Committee. With Newstead's appointment, the Emerson Board will expand to 11 members. With decades of experience spanning both the public and private sectors, Newstead brings comprehensive expertise in policy, corporate governance, government affairs, litigation and compliance to the Emerson Board. Newstead joined Apple's executive team in 2026 as Senior Vice President and General Counsel, overseeing all legal matters. Prior to Apple, Newstead served as Chief Legal Officer and General Counsel at Meta for more than six years, and she held several senior roles across the U.S. government earlier in her career."Jennifer is a highly respected and accomplished leader with more than 30 years of legal and regulatory experience, which will be a strong complement to our best-in-class Board," said James Turley, Chair of the Emerson Board of Directors. "The entire Emerson team is energized and aligned as we execute our differentiated value creation framework." "With the support of our Board, Emerson continues to accelerate innovation and advance our world-class industrial software portfolio," said Lal Karsanbhai, President and Chief Executive Officer of Emerson. "As we work to advance our offerings across a diverse set of industries, Jennifer's unique skillset and perspectives will be a valuable addition to the Board.""Emerson has built a strong track record as a leader in automation and industrial software, and I am honored to join the Board," said Newstead. "Having spent my career at the intersection of law, policy and business, I look forward to contributing to Emerson's strategy to transform global industries with the Company's highly differentiated technology and market-leading solutions."About Jennifer NewsteadJennifer Newstead is Senior Vice President and General Counsel at Apple, where she oversees all of the company's legal matters, including corporate governance, intellectual property, litigation and securities compliance, global security and privacy. Prior to joining Apple in January 2026, she served as Chief Legal Officer at Meta, formerly Facebook, responsible for all global legal and corporate governance matters on behalf of the company. Prior to joining Meta in 2019, Newstead served in senior roles in the U.S. government, most recently as the Senate-confirmed legal adviser of the U.S. Department of State, where she advised on issues of domestic and international law affecting the conduct of U.S. foreign relations. She previously served as General Counsel of the White House Office of Management and Budget and as a Principal Deputy Assistant Attorney General at the U.S. Department of Justice.In the private sector, Newstead spent 12 years as a partner at Davis Polk & Wardwell LLP, advising technology, media and financial services firms on litigation and regulatory matters. Newstead serves on the Board of Trustees at the National Constitution Center, is a member of the Executive Committee at the Association of General Counsel and serves on the Advisory Committee on International Law at the U.S. Department of State. She graduated magna cum laude from Harvard University, where she received her A.B., and received her J.D. from Yale Law School. Following law school, Newstead clerked for Justice Stephen Breyer of the United States Supreme Court and Judge Laurence Silberman of the U.S. Court of Appeals for the DC Circuit. She previously served as an adjunct professor of law at Georgetown University Law Center.About EmersonEmerson (NYSE: EMR) is a global automation leader delivering solutions for the most demanding technology challenges. Headquartered in St. Louis, Missouri, Emerson is engineering the autonomous future, enabling customers to optimize operations and accelerate innovation. For more information, visit Emerson.com.Emerson uses our Investor Relations website, https://ir.emerson.com/, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.ContactsInvestors
Doug Ashby
(314) 553-2197Media
Joseph Sala / Greg Klassen
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449 View original content to download multimedia:https://www.prnewswire.com/news-releases/jennifer-newstead-to-join-emersons-board-of-directors-302762918.htmlSOURCE Emerson Original: Jennifer Newstead to Join Emerson's Board of Directors
US Market News
3月前
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesApril 9, 2026 9:00 AM
InvestorsHub NewsWireAI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesAINewsWire Editorial Coverage: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence directly into manufacturing workflows as a continuous compliance layer. Rather than depending on retrospective audits and manual checks, AI-driven technologies are now capable of monitoring, validating and optimizing production processes in real time to ensure alignment with evolving Good Manufacturing Practice ("GMP") requirements. This transformation is becoming increasingly visible across the sector and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), which operate at the intersection of biotechnology and advanced digital systems, reflecting a broader transition toward intelligent, automated compliance infrastructures. Through its focus on AI, Oncotelic sits alongside other innovation-driven organizations including Rockwell Automation Inc. (NYSE: ROK), Emerson Electric Co. (NYSE: EMR), Thermo Fisher Scientific Inc. (NYSE: TMO) and Danaher Corp. (NYSE: DHR), all of which are contributing to this evolving technological landscape.Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.Regulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing.Current obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.A more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Click here to view the custom infographic of the Oncotelic Therapeutics editorial.Embedded Intelligence Enables Continuous ComplianceHistorically, pharmaceutical manufacturing relied heavily on batch-based testing and manual recordkeeping to verify compliance. While these methods were sufficient in earlier production models, they often introduce delays and create opportunities for human error. Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.This shift supports initiatives from the U.S. Food and Drug Administration ("FDA"), which has encouraged the adoption of advanced manufacturing technologies and continuous production models. Programs such as the FDA's Emerging Technology Program and Advanced Manufacturing Technologies initiative promote the use of innovative systems designed to enhance reliability, improve product quality and minimize the risk of manufacturing failures or supply disruptions. These efforts highlight a transition from reactive oversight to proactive compliance strategies.AI technologies facilitate this transformation by regularly evaluating streams of production data, including variables such as temperature, pressure and material uniformity, to identify anomalies as they occur. Rather than detecting issues during post-production reviews, these systems enable immediate intervention, helping maintain product integrity. This ability supports real-time release testing, a model in which products are evaluated and approved based on live process data instead of delayed laboratory testing.As this approach gains adoption, companies such as Oncotelic Therapeutics are part of a broader ecosystem that increasingly views embedded intelligence as a core component of compliance. Their alignment with AI-enabled platforms reflects a growing understanding that compliance is no longer a discrete checkpoint, but an integrated function operating continuously across the manufacturing lifecycle.Heightened Regulation Accelerates Automation AdoptionRegulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The European Medicines Agency has released detailed guidance on computerized systems and data management, stressing the importance of secure, attributable and contemporaneous records. Likewise, FDA expectations reinforce following ALCOA+ principles, which ensure that data is attributable, legible, contemporaneous, original and accurate.These rising standards are hastening the move toward automation. Manual processes, which have long been standard across pharmaceutical manufacturing, are now seen as potential sources of variability and documentation risk. According to the International Society for Pharmaceutical Engineering, digital transformation initiatives are becoming essential to improving compliance outcomes and reducing operational risk in modern pharmaceutical systems.AI-enhanced automation provides a solution by standardizing workflows and ensuring consistent data capture. These systems automatically generate audit-ready documentation, reducing reliance on human input while improving transparency and accuracy. In sterile manufacturing environments, where contamination risks must be minimized, automation also reduces human involvement, thereby reinforcing compliance outcomes.Within this regulatory environment, Oncotelic Therapeutics represents a wider strategic alignment with innovation driven by compliance requirements. As pharmaceutical companies increasingly prioritize automation and data integrity, organizations leveraging AI-enabled platforms are better positioned to meet evolving regulatory expectations.Pharma 4.0 Drives Intelligent Production EcosystemsThe idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing. Sparked by Industry 4.0, this model integrates digital technologies such as artificial intelligence, robotics and advanced analytics into interconnected production systems. Research indicates that these technologies are transforming biopharma operations by increasing productivity, improving product quality and supporting more agile, data-driven decision-making across the value chain.In such environments, manufacturing systems are fully connected, enabling data to move between equipment, quality systems and supply chain processes. AI-driven analytics use this data to optimize performance, anticipate maintenance needs and ensure compliance. This integration enhances traceability, enabling manufacturers to monitor every stage of production with greater precision.Large pharmaceutical companies are now employing these capabilities. Pfizer Inc. has implemented digital manufacturing programs that leverage AI and data-driven systems to improve efficiency and operational performance. Johnson & Johnson has invested in AI-powered platforms to enhance decision-making and streamline development processes, while Novartis AG is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments. These initiatives demonstrate a broader industry commitment to adopting intelligent manufacturing as a pathway to improved compliance and operational efficiency.Within this context, Oncotelic Therapeutics represents a growing class of entities operating at the intersection of biotechnology and digital innovation. As Pharma 4.0 adoption increases, organizations supporting AI-enabled systems are increasingly positioned to participate in scalable, data-driven manufacturing ecosystems.Efficiency Gains Reduce Cost, RiskThe process of bringing a new pharmaceutical product to market remains both time-consuming and expensive, often requiring more than a decade of development and substantial financial investment. A substantial part of these expenses are caused by high failure rates, increasing process complexity and inefficiencies across development and manufacturing stages. These obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.Deloitte has noted that digital transformation in life sciences manufacturing can boost operational efficiency by streamlining processes, increasing productivity and reducing errors. AI systems can evaluate both real-time and historical data to anticipate possible problems, allowing manufacturers to intervene before issues escalate.Continuous manufacturing, frequently supported by AI and advanced process control technologies, further improves efficiency by reducing reliance on large-batch production. Instead, it enables continuous processing with real-time monitoring, lowering inventory requirements and accelerating time-to-market. The FDA has actively supported this approach, recognizing its ability to improve product quality, reduce costs and provide a more flexible alternative to traditional batch manufacturing.The combination of reduced risk and improved efficiency creates a compelling value proposition for companies operating at the intersection of AI and biotechnology. In this environment, organizations such as Oncotelic Therapeutics reflect the growing importance of platforms capable of supporting intelligent automation and compliance as the industry seeks to manage costs more effectively.AI, Robotics Reshape Biotech InfrastructureA more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Modern manufacturing facilities increasingly rely on robotic systems to automate complex processes such as aseptic filling, material handling and inspection, decreasing the need for human intervention while improving precision and efficiency. In addition, AI-driven systems monitor operations in real time, analyzing data to detect irregularities and optimize performance, supporting continuous compliance.This meeting of technology is especially significant in sterile manufacturing environments, where minimizing human involvement is essential to reducing contamination risk. Robotics provide precision and consistency, while AI systems continuously monitor environmental conditions and process variables. These technologies come together to make integrated systems that sustain both compliance and operational quality.Market data highlights the reach of this transformation. The global pharmaceutical manufacturing sector, already valued in the hundreds of billions of dollars, is expected to reach $1 trillion in the coming years. Investment is increasingly directed toward automation, digital infrastructure and AI-enabled production systems designed to improve efficiency and regulatory compliance. This trend indicates a broader reallocation of capital toward technologies that enhance scalability, precision and operational control.As this movement continues to climb upward, companies aligned with AI-driven platforms may benefit from sustained growth and improved margins. Positioned within this evolving landscape, Oncotelic Therapeutics represents the type of organization that could participate in this transformation, where intelligent automation and integrated compliance redefine pharmaceutical manufacturing.AI and Robotics Drive Next Phase of TransformationArtificial intelligence and robotics are rapidly reshaping industrial operations, enabling companies to improve efficiency, reduce manual intervention and unlock new levels of productivity. Across manufacturing, infrastructure and life sciences, organizations are increasingly deploying intelligent automation systems that combine real-time data, machine learning and advanced robotics to streamline workflows and support decision-making.Rockwell Automation Inc. (NYSE: ROK) announced a major step in real-time intelligence for industrial teams. The company introduced its integration of NVIDIA Nemotron Nano, a purpose-built small language model ("SLM") optimized for FactoryTalk(R) Design Studio(TM) and other Rockwell product workflows. In collaboration with NVIDIA, Rockwell is leveraging the open-source Nemotron-Nano-9B-v2 model and NVIDIA NeMo to deliver an edge-based generative AI capability designed specifically for industrial environments.Emerson Electric Co. (NYSE: EMR) has introduced a new AI-powered environment to enhance upstream lifecycle decision making. Emerson's AspenTech Subsurface Intelligence(TM) ("ASI") is an open, cloud-native agentic environment that incorporates AI to transform the user experience and accelerate subsurface-related decision making while leveraging existing investments in legacy applications. ASI fulfills a critical industry need to work in an agile, multidisciplinary manner, optimize production and improve access to information trapped throughout various parts of the organization.Thermo Fisher Scientific Inc. (NYSE: TMO) integrates AI and robotics into laboratory and semiconductor environments with its Thermo Scientific Vulcan(TM) Automated Lab. The platform is designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system enhances productivity, increases yield and reduces operating costs for semiconductor manufacturers.Danaher Corp. (NYSE: DHR) announced a collaboration designed to enhance life science lab connectivity by integrating automated imaging and detection systems into research workflows. Molecular Devices, LLC., a leading provider of high-performance life science solutions and an operating company of Danaher is partnering with Automata, a London-based lab automation company developing fully integrated, AI-ready platforms for life science researchers. As labs face mounting pressure to boost throughput and data quality while managing limited hands-on resources, new integrations between Molecular Devices' imaging and detection systems and Automata's LINQ platform will provide a scalable, interoperable foundation for fully connected research workflows.These developments reflect a broader transformation across industrial and scientific sectors, where AI and robotics are becoming foundational technologies rather than experimental tools. As companies continue to integrate intelligent systems into core operations, these advancements highlight the growing importance of automation in driving efficiency, scalability and long-term competitiveness across the global economy.For more information, visit Oncotelic Therapeutics Inc.
Original: AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
US Market News
5月前
Emerson Reports First Quarter 2026 Results; Updates 2026 OutlookFebruary 3, 2026 4:05 PM
PR Newswire (US)
ST. LOUIS, Feb. 3, 2026 /PRNewswire/ -- Emerson (NYSE: EMR) today reported results for its first quarter ended December 31, 2025 and updated its full year outlook for fiscal 2026. Emerson also declared a quarterly cash dividend of $0.555 per share of common stock payable March 10, 2026 to stockholders of record on February 13, 2026.
(dollars in millions, except per share)2025 Q12026 Q1ChangeUnderlying Orders1
9 %Net Sales$4,175$4,3464 %Underlying Sales2
2 %Pretax Earnings$775$775
Margin18.6 %17.8 %(80) bpsAdjusted Segment EBITA3$1,169$1,203
Margin28.0 %27.7 %(30) bpsGAAP Earnings Per Share$1.02$1.075 %Adjusted Earnings Per Share4$1.38$1.466 %Operating Cash Flow$777$699(10) %Free Cash Flow$694$602(13) %Management Commentary"Emerson met sales commitments and exceeded expectations for profitability as our global teams continue to execute well," said Emerson President and Chief Executive Officer Lal Karsanbhai. "We delivered a fourth consecutive quarter of strong underlying orders growth, and we are experiencing robust demand for our automation technology, led by Software & Systems, with strength in North America, India and the Middle East & Africa."Karsanbhai continued, "Emerson is accelerating innovation, introducing new products and delivering on the critical programs we highlighted at our 2025 investor conference. These releases advance our capabilities in software-defined automation and further enhance our leadership position in high-growth verticals."2026 OutlookThe following tables summarize the fiscal year 2026 guidance framework. As we pivot capital allocation to returning cash to shareholders, the 2026 outlook assumes returning ~$2.2B through ~$1B share repurchases and ~$1.2B of dividends.
2026 Q22026Net Sales Growth3% - 4%~5.5%Underlying Sales Growth1% - 2%~4%Earnings Per Share$1.06 - $1.11$4.78 - $4.93Amortization of intangibles~$0.35~$1.38Restructuring and related costs~$0.06~$0.14Acquisition/divestiture fees and related costs~$0.02~$0.06Discrete taxes~$0.01~$0.04Adjusted Earnings Per Share$1.50 - $1.55$6.40 - $6.55Operating Cash Flow
$4.0B - $4.1BFree Cash Flow
$3.5B - $3.6BShare Repurchase
~$1.0B1 Underlying orders do not include AspenTech.2 Underlying sales exclude the impact of currency translation, and significant acquisitions and divestitures.3 Adjusted segment EBITA represents segment earnings less restructuring and intangibles amortization expense.4 Adjusted EPS excludes intangibles amortization expense, restructuring and related costs, acquisition/divestiture gains, losses, fees and related costs, and discrete taxes.Conference CallToday, beginning at 3:30 p.m. Central Time / 4:30 p.m. Eastern Time, Emerson management will discuss the first quarter results during an investor conference call. Participants can access a live webcast available at https://ir.emerson.com at the time of the call. A replay of the call will be available for 90 days. Conference call slides will be posted in advance of the call on the company website.About EmersonEmerson (NYSE: EMR) is a global automation leader delivering solutions for the most demanding technology challenges. Headquartered in St. Louis, Missouri, Emerson is engineering the autonomous future, enabling customers to optimize operations and accelerate innovation. For more information, visit Emerson.com.Forward-Looking and Cautionary StatementsStatements in this press release that are not strictly historical may be "forward-looking" statements, which represent management's expectations, based on currently available information. Actual results, performance or achievements could differ materially from those expressed in any forward-looking statement. Any forward-looking statements in this press release speak only as of the date of this press release. Emerson undertakes no obligation to update any such statements to reflect new information or later developments. Examples of risks and uncertainties that may cause our actual results or performance to be materially different from those expressed or implied by forward looking statements include the scope, duration and ultimate impacts of the Russia-Ukraine and other global conflicts, as well as economic and currency conditions, market demand, pricing, protection of intellectual property, cybersecurity, tariffs, competitive and technological factors, inflation, among others, as set forth in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. The outlook contained herein represents the Company's expectation for its consolidated results, other than as noted herein.Emerson uses our Investor Relations website, https://ir.emerson.com, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts and social media. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.Investors:Media:Doug AshbyJoseph Sala / Greg Klassen(314) 553-2197Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449(tables attached)
Table 1EMERSON AND SUBSIDIARIESCONSOLIDATED OPERATING RESULTS(AMOUNTS IN MILLIONS EXCEPT PER SHARE, UNAUDITED)
Quarter Ended Dec 31,
2024
2025
Net sales$ 4,175
$ 4,346Cost and expenses
Cost of sales1,940
2,035 SG&A expenses1,224
1,242 Other deductions, net228
204 Interest expense, net8
90Earnings before income taxes775
775Income taxes182
169Net earnings593
606Less: Noncontrolling interests in subsidiaries8
1Net earnings common stockholders$ 585
$ 605
Diluted avg. shares outstanding571.1
564.1
Diluted earnings per share common stockholders
Diluted earnings per common share$ 1.02
$ 1.07
Quarter Ended Dec 31,
2024
2025Other deductions, net
Amortization of intangibles$ 229
$ 205Restructuring costs11
9Other(12)
(10)Total$ 228
$ 204
Table 2EMERSON AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(DOLLARS IN MILLIONS, UNAUDITED)
Sept 30, 2025
Dec 31, 2025Assets
Cash and equivalents$ 1,544
$ 1,748 Receivables, net3,101
2,972 Inventories2,213
2,353 Other current assets1,725
1,770Total current assets8,583
8,843 Property, plant & equipment, net2,871
2,867 Goodwill18,193
18,182 Other intangibles9,458
9,205 Other2,859
2,842Total assets$ 41,964
$ 41,939
Liabilities and equity
Short-term borrowings and current maturities of long-term debt$ 4,797
$ 5,832 Accounts payable1,384
1,339 Accrued expenses3,616
3,349Total current liabilities9,797
10,520 Long-term debt8,319
7,575 Other liabilities3,550
3,552Equity
Common stockholders' equity 20,282
20,277 Noncontrolling interests in subsidiaries16
15Total equity20,298
20,292Total liabilities and equity$ 41,964
$ 41,939
Table 3EMERSON AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(DOLLARS IN MILLIONS, UNAUDITED)
Three Months Ended Dec 31,
2024
2025Operating activities
Net earnings
$ 593
$ 606Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization
383
359 Stock compensation
68
55 Changes in operating working capital
(154)
(357) Other, net
(113)
36 Cash provided by operating activities
777
699
Investing activities
Capital expenditures
(83)
(97)Purchases of businesses, net of cash and equivalents acquired
(37)
—Other, net
(22)
(28) Cash used in investing activities
(142)
(125)
Financing activities
Net increase (decrease) in short-term borrowings
2
(485)Proceeds from short-term borrowings greater than three months
—
3,473Payments of short-term borrowings greater than three months
—
(2,099)Payments of long-term debt
(2)
(587)Dividends paid
(301)
(312)Purchases of common stock
(899)
(250)Other, net
(91)
(104) Cash used in financing activities
(1,291)
(364)
Effect of exchange rate changes on cash and equivalents
(98)
(6)Increase (decrease) in cash and equivalents
(754)
204Beginning cash and equivalents
3,588
1,544Ending cash and equivalents
$ 2,834
$ 1,748
Table 4EMERSON AND SUBSIDIARIESSEGMENT SALES AND EARNINGS(DOLLARS IN MILLIONS, UNAUDITED)
The following tables show results for the Company's segments on an adjusted segment EBITA basis and are intended to
supplement the Company's results of operations, including its segment earnings which are defined as earnings before
interest and taxes. The Company defines adjusted segment and total segment EBITA as segment earnings excluding
intangibles amortization expense, and restructuring and related expense. Adjusted segment and total segment EBITA,
and adjusted segment and total segment EBITA margin are measures used by management and may be useful for
investors to evaluate the Company's segments' operational performance.
Quarter Ended Dec 31,
2024
2025
Reported
Underlying
Sales
Control Systems & Software$ 1,023
$ 1,044
2 %
— %
Test & Measurement359
409
14 %
11 %
Software & Systems$ 1,382
$ 1,453
5 %
3 %
Sensors972
996
2 %
1 %
Final Control1,334
1,394
4 %
2 %
Intelligent Devices$ 2,306
$ 2,390
4 %
2 %
Safety & Productivity$ 487
$ 503
3 %
1 %
Total$ 4,175
$ 4,346
4 %
2 %
Sales Growth by Geography
Quarter Ended
Dec 31,
Americas3 %
Europe 3 %
Asia, Middle East & Africa— %
Table 4 cont.
Quarter Ended Dec 31,
Quarter Ended Dec 31,
2024
2025
As Reported
(GAAP)
Adjusted
EBITA
(Non-GAAP)
As
Reported
(GAAP)
Adjusted
EBITA
(Non-GAAP)Earnings
Control Systems & Software$ 208
$ 337
$ 232
$ 334 Margins20.3 %
33.0 %
22.2 %
31.9 %Test & Measurement(13)
91
14
121 Margins(3.6) %
25.5 %
3.6 %
29.7 %Software & Systems$ 195
$ 428
$ 246
$ 455 Margins14.1 %
31.1 %
17.0 %
31.3 %
Sensors285
296
266
282 Margins29.3 %
30.5 %
26.7 %
28.3 %Final Control305
341
331
361 Margins22.9 %
25.5 %
23.8 %
25.9 %Intelligent Devices$ 590
$ 637
$ 597
$ 643 Margins25.6 %
27.6 %
25.0 %
26.9 %
Safety & Productivity$ 96
$ 104
$ 97
$ 105 Margins19.7 %
21.3 %
19.2 %
20.9 %
Corporate items and interest expense, net:
Stock compensation(68)
(66)
(55)
(51)Unallocated pension and postretirement costs27
27
29
29Corporate and other(57)
(34)
(49)
(40)Interest expense, net(8)
—
(90)
—
Pretax Earnings / Adjusted EBITA$ 775
$ 1,096
$ 775
$ 1,141 Margins18.6 %
26.3 %
17.8 %
26.3 %
Supplemental Total Segment Earnings:
Adjusted Total Segment EBITA
$ 1,169
$ 1,203 Margins
28.0 %
27.7 %
Table 4 cont.
Quarter Ended Dec 31,
Quarter Ended Dec 31,
2024
2025
Amortization of Intangibles1
Restructuring and Related Costs2
Amortization of Intangibles1
Restructuring and Related Costs2
Control Systems & Software$ 127
$ 2
$ 101
$ 1
Test & Measurement105
(1)
107
—
Software & Systems$ 232
$ 1
$ 208
$ 1
Sensors10
1
11
5
Final Control29
7
28
2
Intelligent Devices$ 39
$ 8
$ 39
$ 7
Safety & Productivity$ 7
$ 1
$ 7
$ 1
Corporate—
3
—
2
Total$ 278
$ 13
$ 254
$ 11
1 Amortization of intangibles includes $49 reported in cost of sales for the three months ended December 31, 2024 and 2025.2 Restructuring and related costs includes $2 reported in selling, general and administrative expenses for the three months ended December 31, 2024 and 2025.
Quarter Ended Dec 31,Depreciation and Amortization2024
2025Control Systems & Software$ 149
$ 122Test & Measurement118
119Software & Systems267
241
Sensors31
33Final Control55
56Intelligent Devices86
89
Safety & Productivity19
19
Corporate11
10Total$ 383
$ 359
Table 5EMERSON AND SUBSIDIARIESADJUSTED CORPORATE AND OTHER SUPPLEMENTAL(DOLLARS IN MILLIONS, UNAUDITED)The following table shows the Company's stock compensation and corporate and other expenses on an adjusted basis.
The Company's definition of adjusted stock compensation excludes integration-related stock compensation expense. The
Company's definition of adjusted corporate and other excludes corporate restructuring and related costs, first year
purchase accounting related items and transaction fees, and certain gains, losses or impairments. This metric is useful for
reconciling from total adjusted segment EBITA to the Company's consolidated adjusted EBITA.
Quarter Ended Dec 31,
2024
2025
Stock compensation (GAAP)
$ (68)
$ (55)
Integration-related stock compensation expense
2
4
Adjusted stock compensation (non-GAAP)
$ (66)
$ (51)
Quarter Ended Dec 31,
2024
2025
Corporate and other (GAAP)
$ (57)
$ (49)
Corporate restructuring and related costs
3
2
Acquisition / divestiture costs
20
7
Adjusted corporate and other (non-GAAP)
$ (34)
$ (40)
Table 6EMERSON AND SUBSIDIARIESADJUSTED EBITA & EPS SUPPLEMENTAL(AMOUNTS IN MILLIONS EXCEPT PER SHARE, UNAUDITED)
The following tables, which show results on an adjusted EBITA basis and diluted earnings per share on an adjusted basis,
are intended to supplement the Company's discussion of its results of operations herein. The Company defines adjusted
EBITA as earnings excluding interest expense, net, income taxes, intangibles amortization expense, restructuring
expense, first year purchase accounting related items and transaction fees, and certain gains, losses or impairments.
Adjusted earnings per share excludes intangibles amortization expense, restructuring expense, first year purchase
accounting related items and transaction-related costs, discrete taxes, and certain gains, losses or impairments. Adjusted
EBITA, adjusted EBITA margin, and adjusted earnings per share are measures used by management and may be useful
for investors to evaluate the Company's operational performance.
Quarter Ended Dec 31,
2024
2025Pretax earnings $ 775
$ 775Percent of sales18.6 %
17.8 %Interest expense, net8
90Amortization of intangibles278
254Restructuring and related costs13
11Acquisition/divestiture fees and related costs22
11Adjusted EBITA$ 1,096
$ 1,141Percent of sales26.3 %
26.3 %
Quarter Ended Dec 31,
2024
2025GAAP earnings per share$ 1.02
$ 1.07Amortization of intangibles0.31
0.35Restructuring and related costs0.02
0.02Acquisition/divestiture fees and related costs0.03
0.01Discrete taxes—
0.01Adjusted earnings per share$ 1.38
$ 1.46
Table 6 cont.
Quarter Ended December 31, 2025
Pretax
Earnings
Income
Taxes
Net
Earnings
Non-
ControllingInterests
Net
Earnings
Common
Stockholders
Diluted
Earnings
Per
ShareAs reported (GAAP)$ 775
$ 169
$ 606
$ 1
$ 605
$ 1.07Amortization of intangibles254159
195
—
195
0.35Restructuring and related costs1123
8
—
8
0.02Acquisition/divestiture fees and related costs11
2
9
—
9
0.01Discrete Taxes—
(5)
5
—
5
0.01Adjusted (non-GAAP)$ 1,051
$ 228
$ 823
$ 1
$ 822
$ 1.46Interest expense, net90
Adjusted EBITA (non-GAAP)$ 1,141
1 Amortization of intangibles includes $49 reported in cost of sales.2 Restructuring and related costs includes $2 reported in selling, general and administrative expenses.
Reconciliations of Non-GAAP Financial Measures & Other
Table 8
Reconciliations of Non-GAAP measures with the most directly comparable GAAP measure (dollars in millions,
except per share amounts). See tables 4 through 7 for additional non-GAAP reconciliations.
2026 Q1 Underlying Sales ChangeReported(Favorable) /
Unfavorable FX(Acquisitions) /
DivestituresUnderlyingControl Systems & Software2 %(2) %— %— %Test & Measurement14 %(3) %— %11 %Software & Systems5 %(2) %— %3 %Sensors2 %(1) %— %1 %Final Control4 %(2) %— %2 %Intelligent Devices4 %(2) %— %2 %Safety and Productivity3 %(2) %— %1 %Emerson4 %(2) %— %2 % Underlying Growth Guidance2026 Q2
Guidance2026GuidanceReported (GAAP)3% - 4%~5.5%(Favorable) / Unfavorable FX~(2 pts)~(1.5 pts)(Acquisitions) / Divestitures--Underlying (non-GAAP)1% - 2%~4% 2025 Q1 Adjusted Segment EBITAEBITEBIT MarginAmortizationof IntangiblesRestructuring
and Related
CostsAdjusted
Segment
EBITAAdjusted
Segment
EBITA
MarginControl Systems & Software$ 20820.3 %$ 127$ 2$ 33733.0 %Test & Measurement(13)(3.6) %105(1)9125.5 %Software & Systems$ 19514.1 %$ 232$ 1$ 42831.1 %Sensors28529.3 %10129630.5 %Final Control30522.9 %29734125.5 %Intelligent Devices$ 59025.6 %$ 39$ 8$ 63727.6 %Safety & Productivity$ 9619.7 %$ 7$ 1$ 10421.3 %
2026 Q1 Adjusted Segment EBITAEBITEBIT MarginAmortization
of
IntangiblesRestructuring
and Related
CostsAdjusted
Segment
EBITAAdjusted
Segment
EBITA
MarginControl Systems & Software$ 23222.2 %$ 101$ 1$ 33431.9 %Test & Measurement143.6 %107—12129.7 %Software & Systems$ 24617.0 %$ 208$ 1$ 45531.3 %Sensors26626.7 %11528228.3 %Final Control33123.8 %28236125.9 %Intelligent Devices$ 59725.0 %$ 39$ 7$ 64326.9 %Safety & Productivity$ 9719.2 %$ 7$ 1$ 10520.9 %
Total Adjusted Segment EBITA
2025 Q12026 Q1Pretax earnings (GAAP)
$ 775$ 775Margin
18.6 %17.8 %Corporate items and interest expense, net
106165Amortization of intangibles
278254Restructuring and related costs
109Adjusted segment EBITA (non-GAAP)
$ 1,169$ 1,203Margin
28.0 %27.7 % Free Cash Flow
2025 Q12026 Q1
2026E($ in billions)
Operating cash flow (GAAP)
$ 777$ 699
$4.0 - $4.1
Capital expenditures
(83)(97)
~(0.45)
Free cash flow (non-GAAP)
$ 694$ 602
$3.5 - $3.6
Note 1: Underlying sales and orders exclude the impact of currency translation and significant acquisitions and divestitures.Note 2: All fiscal year 2026E figures are approximate, except where range is given.
View original content to download multimedia:https://www.prnewswire.com/news-releases/emerson-reports-first-quarter-2026-results-updates-2026-outlook-302677917.htmlSOURCE Emerson
Original: Emerson Reports First Quarter 2026 Results; Updates 2026 Outlook
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
ihubstockmover
2月前
Monksdream
2年前
fuzzy
5年前
Nebuchadnezzar
6年前
conix
6年前
whytestocks
6年前
inforthemoney2
8年前
ValueInvestor15
9年前
Beandog
9年前
blackbandit
12年前
Penny Roger$
14年前
メールアドレスで登録
